Vertex Pharmaceuticals Incorporated (VRTX): Price and Financial Metrics
Vertex Pharmaceuticals Incorporated (VRTX)
Today's Latest Price: $214.54 USD
Updated Oct 20 4:00pm
Add VRTX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
VRTX Stock Summary
- VRTX has a higher market value than 96.61% of US stocks; more precisely, its current market capitalization is $57,435,651,820.
- In terms of twelve month growth in earnings before interest and taxes, Vertex Pharmaceuticals Inc is reporting a growth rate of 158.49%; that's higher than 92.05% of US stocks.
- The volatility of Vertex Pharmaceuticals Inc's share price is greater than that of only 6.43% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to Vertex Pharmaceuticals Inc, a group of peers worth examining would be MU, AMAT, LRCX, EA, and XLNX.
- VRTX's SEC filings can be seen here. And to visit Vertex Pharmaceuticals Inc's official web site, go to www.vrtx.com.
VRTX Stock Price Chart Interactive Chart >
VRTX Price/Volume Stats
| Current price | $214.54 | 52-week high | $306.08 |
| Prev. close | $220.51 | 52-week low | $174.82 |
| Day low | $214.48 | Volume | 2,924,700 |
| Day high | $222.62 | Avg. volume | 1,815,490 |
| 50-day MA | $264.36 | Dividend yield | N/A |
| 200-day MA | $259.28 | Market Cap | 55.88B |
Vertex Pharmaceuticals Incorporated (VRTX) Company Bio
Vertex Pharmaceuticals engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing its research and early-stage development programs. The company was founded in 1989 and is based in Boston, Massachusetts.
VRTX Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $214.54 | $44312.91 | 19996% |
Below please find a table outlining a discounted cash flow forecast for VRTX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Vertex Pharmaceuticals Inc ranked in the 97th percentile in terms of potential gain offered. Our DCF model suggests the stock is undervalued by 20094.5%; returns of such proportions should be viewed with some skepticism, though. The most interesting components of our discounted cash flow analysis for Vertex Pharmaceuticals Inc ended up being:
- In the past 3.75 years, Vertex Pharmaceuticals Inc has a compound free cash flow growth rate of 2.59%; that's better than 93.01% of cash flow producing equities in the Healthcare sector, where it is classified.
- The business' balance sheet reveals debt to be 1% of the company's capital (with equity being the remaining amount). Approximately merely 4.95% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- VRTX's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 53.34% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 19602% |
| 1% | 19799% |
| 2% | 19996% |
| 3% | 20193% |
| 4% | 20390% |
| 5% | 20587% |
Want more companies with a valuation profile/forecast similar to that of Vertex Pharmaceuticals Inc? See KMDA, ASNB, GEN, AMEH, and AMRX.
Loading social stream, please wait...